A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NCT07699328)
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
🩺 Plain-English Summary (8th-Grade Level)
This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The study includes a Phase 1a dose-escalation portion, a Phase 1b dose-expansion portion, and a Phase 2 evaluation. The study is designed to determine the maximum tolerated dose and recommended Phase 2 dose of VRN110755 and to evaluate preliminary and confirmatory antitumor activity in patients with EGFR-mutant NSCLC, including patients with acquired resistance following EGFR tyrosine kinase inhibitor therapy.
Who can join: Review the eligibility criteria below.
Location: Southern Oncology Clinical Research Unit — Bedford Park, South Australia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- Southern Oncology Clinical Research Unit — Bedford Park, South Australia
- Monash Medical Centre Clayton — Clayton, Victoria
- Princess Margaret Cancer Centre — Toronto, Ontario
- AP-HM Hôpital Nord — Marseille, Bouches-du-Rhône
- Centre Georges François Leclerc — Dijon, Côte-d'Or
- Prince of Wales Hospital — Hong Kong,
- Queen Mary Hospital — Hong Kong,
- Hospital Umum Sarawak — Kuching, Sarawak
- Hospital Kuala Lumpur — Kuala Lumpur,
- University Malaya Medical Centre — Kuala Lumpur,
- Institut Kanser Negara — Putrajaya,
- National Cancer Centre Singapore — Singapore,
- Tan Tock Seng Hospital — Singapore,
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do
- The Catholic University of Korea, St. Vincent's Hospital — Suwon, Gyeonggi-do
- Chungbuk National University Hospital — Cheongju-si, North Chungcheong
- Severance Hospital Yonsei University Health System — Seoul,
- Samsung Medical Center — Seoul,
- ICO Badalona - Hospital Universitari Germans Trias i Pujol — Badalona, Barcelona
- ICO l'Hospitalet - Hospital Duran i Reynals — L'Hospitalet de Llobregat, Barcelona
- Hospital Universitario 12 de Octubre — Madrid,
- Hospital Regional Universitario de Málaga - Hospital Civil — Málaga,
- Kaohsiung Medical University Chung-Ho Memorial Hospital — Kaohsiung City,
- Taichung Veterans General Hospital — Taichung,
- National Taiwan University Hospital — Taipei,
📞 Contact the Study Coordinator
Phone: 00 82 32 219 7849
Email: somi@voronoi.io
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in EGFR-Mutant Non-Small Cell Lung Cancer
Explore by condition: All EGFR-Mutant Non-Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.